HUP9800731A2 - Eljárás ivarsejt osztódás stimulálására - Google Patents

Eljárás ivarsejt osztódás stimulálására

Info

Publication number
HUP9800731A2
HUP9800731A2 HU9800731A HUP9800731A HUP9800731A2 HU P9800731 A2 HUP9800731 A2 HU P9800731A2 HU 9800731 A HU9800731 A HU 9800731A HU P9800731 A HUP9800731 A HU P9800731A HU P9800731 A2 HUP9800731 A2 HU P9800731A2
Authority
HU
Hungary
Prior art keywords
meiosis
stimulation
vivo
compound
pharmaceuticals
Prior art date
Application number
HU9800731A
Other languages
English (en)
Inventor
Anne Grete Byskov
Frederik Christian Gronvald
Erling Guddal
Lars Nordholm
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HUP9800731A2 publication Critical patent/HUP9800731A2/hu
Publication of HUP9800731A3 publication Critical patent/HUP9800731A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/061—Sperm cells, spermatogonia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya eljárás csírasejtekben meiőzis stiműlálására. Atalálmány szerint úgy járnak el, hőgy a sejtnek in vivő, ex vivő vagyin vitrő útőn egy őlyan vegyület hatásős mennyiségét adagőlják, amelyvalamely endőgén meiőzist aktiváló vegyület őlyan kőncentrációratörténő akkűműlációját eredményezi, amellyel a meiőzis indűkálódik.A találmány szerinti eljárás gyógyszerészetben alkalmazható.ŕ
HU9800731A 1995-03-06 1996-03-06 Stimulation of meiosis HUP9800731A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK23295 1995-03-06
DK30995 1995-03-24

Publications (2)

Publication Number Publication Date
HUP9800731A2 true HUP9800731A2 (hu) 1998-07-28
HUP9800731A3 HUP9800731A3 (en) 2000-03-28

Family

ID=26063579

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800731A HUP9800731A3 (en) 1995-03-06 1996-03-06 Stimulation of meiosis

Country Status (13)

Country Link
US (1) US5830757A (hu)
EP (1) EP0813595A1 (hu)
JP (1) JPH11501806A (hu)
KR (1) KR19980702624A (hu)
AU (1) AU717180B2 (hu)
BR (1) BR9607673A (hu)
CA (1) CA2214126A1 (hu)
CZ (1) CZ279797A3 (hu)
HU (1) HUP9800731A3 (hu)
NO (1) NO974089D0 (hu)
PL (1) PL322106A1 (hu)
RU (1) RU2188006C2 (hu)
WO (1) WO1996027658A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2275683A1 (en) * 1996-12-20 1998-07-02 Frederik Christian Gronvald Meiosis regulating compounds
ES2189173T3 (es) * 1997-05-16 2003-07-01 Akzo Nobel Nv Derivados de 20-aril-5alfa-pregnano.
US6262282B1 (en) * 1997-06-04 2001-07-17 Akzo Nobel N.V. 17β-allyloxy(thio)alkyl-androstane derivatives for the modulation of meiosis
AU2160999A (en) 1997-12-18 1999-07-12 Akzo Nobel N.V. 17beta-aryl (arylmethyl) oxy(thio)alkyl -androstane derivatives
IL139241A0 (en) 1998-05-13 2001-11-25 Novo Nordisk As Meiosis regulating compounds
EP0957108A1 (en) * 1998-05-14 1999-11-17 Schering Aktiengesellschaft Unsaturated cholestane derivatives, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments
CA2333320A1 (en) * 1998-05-26 1999-12-02 Schering Aktiengesellschaft Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound
EP1087988A1 (en) * 1998-06-19 2001-04-04 Novo Nordisk A/S Meiosis regulating compounds
WO2000035938A1 (en) * 1998-12-11 2000-06-22 Akzo Nobel N.V. 22s-hydroxycholesta-8, 14-diene derivatives with meiosis regulating activity
IL143735A0 (en) * 1999-02-10 2002-04-21 Schering Ag Unsaturated cholestane derivatives and their use for the preparation of meiosis regulating medicaments
WO2000050065A1 (en) * 1999-02-24 2000-08-31 Novo Nordisk A/S Treatment of infertility
BR0008468A (pt) * 1999-02-24 2002-02-05 Novo Nordisk As Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos
IL144529A0 (en) * 1999-02-26 2002-05-23 Novo Nordisk As Meiosis activating sterol augments implantation rate
DK1163258T3 (da) * 1999-03-09 2003-03-31 Akzo Nobel Nv Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis
JP2002544136A (ja) * 1999-05-10 2002-12-24 シエーリング アクチエンゲゼルシャフト １４β−Ｈ−ステロール類、それらを含んで成る医薬組成物、及び減数分裂調節医薬の調節のためのそれらの誘導体の使用
JP2003509365A (ja) 1999-09-16 2003-03-11 ノボ ノルディスク アクティーゼルスカブ Ｉｖｆ用の組成物
EP1127890A1 (en) 2000-02-22 2001-08-29 Schering Aktiengesellschaft Steroid derivatives with an additional ring annulated to ring A and use of these derivatives for the preparation of meiosis regulating medicaments
EP1285058A2 (en) * 2000-05-18 2003-02-26 Schering Aktiengesellschaft Fertilization of aged oocytes
EP1216701A1 (en) * 2000-12-22 2002-06-26 Schering Aktiengesellschaft Process to increase the concentration of meiosis-activating sterols (MAS) in the cholesterol synthesis and the use of potent inhibitors in the process
EP1245572A1 (en) * 2001-03-26 2002-10-02 Schering Aktiengesellschaft Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation
US20050020666A1 (en) * 2003-07-25 2005-01-27 Dabur Research Foundation Cardioprotective agents
JP2009538332A (ja) * 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド メラトニンアゴニスト治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716777A (en) * 1994-06-23 1998-02-10 Novo Nordisk A/S Regulation of meiosis using sterols

Also Published As

Publication number Publication date
MX9706565A (es) 1997-11-29
RU2188006C2 (ru) 2002-08-27
US5830757A (en) 1998-11-03
HUP9800731A3 (en) 2000-03-28
JPH11501806A (ja) 1999-02-16
EP0813595A1 (en) 1997-12-29
NO974089L (no) 1997-09-05
CZ279797A3 (cs) 1998-01-14
CA2214126A1 (en) 1996-09-12
NO974089D0 (no) 1997-09-05
WO1996027658A1 (en) 1996-09-12
AU717180B2 (en) 2000-03-16
AU4784596A (en) 1996-09-23
KR19980702624A (ko) 1998-08-05
BR9607673A (pt) 1998-06-16
PL322106A1 (en) 1998-01-05

Similar Documents

Publication Publication Date Title
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
DK0839154T3 (da) Biologiske aktive peptider og præparater samt anvendelse deraf
NO981944D0 (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
DE69622265D1 (de) Trizyklische verbindungen zur behandlung von zellproliferativen störungen
GB2340121B (en) Delivery system
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
MX9206577A (es) COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES
FI965144A0 (fi) Sterolijohdannaiset käytettäviksi meioosin säätelyyn
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
ATE435648T1 (de) Derivaten von nodulisporen säure
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ATE119770T1 (de) Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE459355T1 (de) Verfahren zur behandlung von erkrankungen mit mangel an thiolhaltiger verbindung
DE69631542D1 (de) Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
ATE208200T1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
ES2170377T3 (es) Composicion que contiene quitosana.
DE69331942D1 (de) Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
DK0795008T3 (da) Humane hypertrofe chondrocyt-cellelinjer
ATE203010T1 (de) Verwendung von aminoalkoholderivaten als arzneimittel, derivate sowie verfahren zu deren herstellung
ATE225664T1 (de) Verwendung von humanem alpha 1-sauren glycoprotein zur herstellung einer pharmazeutischen präparation
UA30366A (uk) Спосіб лікування псоріазу
RU95111293A (ru) Способ терапии острой пневмонии